Beta-carboline reversible MAO-A inhibitor (DYRK1A inhibitor)

Plain-language summaryIntrigue 68 / 100

Harmine is the second major beta-carboline in ayahuasca and Syrian rue, with the same reversible MAO-A inhibition that lets oral DMT work. What makes harmine separately interesting is its activity as a DYRK1A kinase inhibitor at low nanomolar potency. DYRK1A regulates pancreatic beta-cell proliferation, and harmine has emerged as a tool compound for stimulating beta-cell regrowth in diabetes research, where adult beta-cells have been considered essentially non-replicative. That diabetes angle is genuinely novel and has driven medicinal chemistry programs to build cleaner DYRK1A inhibitors without the MAO baggage. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

49/100

Dual MAO-A and DYRK1A inhibitor; the reference probe that opened human beta-cell regeneration research

Harmine has been around long enough that it almost feels unfair to call it a research compound. Beta-carboline alkaloids from Peganum harmala were being studied before most modern pharmacology existed. The MAO-A inhibition story is mature, well-documented, and not particularly interesting by itself: reversible MAOI in a crowded class, solid selectivity over MAO-B, short plasma half-life around 1 to 3 hours. If that were the whole story, we’d score it low and move on.

The DYRK1A angle is what keeps harmine on our radar. The Bhatt lab at Icahn Mount Sinai (now Garcia-Ocana at Cedars-Sinai) dropped a Nature Medicine paper in 2015 showing that harmine, operating as a DYRK1A kinase inhibitor at roughly 30 nM IC50, could drive human pancreatic beta-cell proliferation at a level nobody had seen before with a small molecule. Beta-cell regeneration has been a target for type 1 and type 2 diabetes research for decades; thats genuinely hard biology, and harmine hit it in a way that attracted serious attention. Follow-up work confirmed the effect in humanized mouse models, and the field has since spawned cleaner derivative compounds now entering Phase 1 trials.

The evidence situation is complicated. The beta-cell story is well-replicated within the Bhatt/Garcia-Ocana group and their collaborators, and the preclinical methodology is solid. But the work remains consortium-concentrated. You get multi-lab confirmation in the sense that several groups have used harmine as a probe, but the primary mechanistic claims on beta-cell expansion still trace back to a tight cluster of investigators. That’s not a knock; the data quality is real. It just means we’re not looking at the kind of multi-institutional replication you’d want before calling it settled science.

As a bench tool, harmine earns its place. It’s the reference beta-carboline for ayahuasca pharmacology research, and it’s the compound that opened the DYRK1A/beta-cell proliferation story as a tractable target. More selective DYRK1A inhibitors have emerged since (GNF4877, INDY, the leucettine series), so if youre doing clean kinase biology, those are better probes now. But harmine’s dual MAO-A/DYRK1A activity is genuinely useful when you want to understand what the full beta-carboline scaffold does across both axes simultaneously, or when sourcing a historically-grounded reference standard for the class.

What we don’t love: the MAO-A inhibition is a real confound for any harmine-specific mechanistic experiment, and the CNS activity profile makes whole-animal results harder to interpret cleanly. What we like: it remains the canonical probe for a research area with real translational momentum, and the derivative pipeline it inspired is one of the more interesting small-molecule diabetes programs currently running. Solid established-active scoring, with genuine upside in the DYRK1A space if replication continues to hold outside the founding consortium.

Novelty: 42
Mechanism promise: 62
In-category differentiation: 42
Evidence quality: 48
Translational signal: 45
Research bench value: 58

Rationale Harmine’s MAO-A inhibition is mature and unremarkable, but its DYRK1A activity at roughly 30 nM IC50 and the resulting beta-cell proliferation story make it a genuine established-active probe. Evidence is solid but consortium-concentrated; more selective DYRK1A tools now exist, keeping differentiation modest and novelty anchored in the mid-established range.

Beta-carboline reversible MAO-A inhibitor (DYRK1A inhibitor)

A beta-carboline alkaloid from Peganum harmala; a reversible MAO-A inhibitor and DYRK1A kinase inhibitor of interest in beta-cell biology.

Abstract

Harmine (7-methoxy-1-methyl-9H-pyrido[3,4-b]indole; CAS 442-51-3; molecular formula C13H12N2O; molecular weight 212.25) is a beta-carboline alkaloid from Peganum harmala and Banisteriopsis caapi. The compound is a reversible MAO-A inhibitor with similar selectivity profile to harmaline but with the additional well-characterized activity of DYRK1A kinase inhibition (IC50 approximately 30 nM). The DYRK1A activity has generated substantial interest in diabetes research: harmine and related DYRK1A inhibitors stimulate human pancreatic beta-cell proliferation in vitro and in vivo, a long-sought target for diabetes regenerative therapy. Phase 1 trials of derivatives are underway. Plasma half-life is approximately 1 to 3 hours. Used as a research probe for both ayahuasca pharmacology and beta-cell regenerative biology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-338Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Beta-carboline reversible MAO-A inhibitor (DYRK1A inhibitor)

Harmine

Abstract

Read the full monograph